TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum-inputs (vergelijkbare managers):
breedte van houders -4.5% ·
aandelenstroom -8.7% ·
netto nieuwe posities -4.8%
· formule
Brede distributie: dalende aandelen en minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 151 | +7 | 369.28M | $12.48B | +9 | −1 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | n/a | n/a |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | n/a | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | n/a | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | n/a |
| Q2 2024 | 19 | n/a | 61.88M | $1.01B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passief) | 19.41M | n/a | $427.89M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passief) | 9.28M | +5.6% | $203.64M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Duquesne Family Office ✦ | 9.00M | +530.1% | $198.30M | 5.6% | ▲ Add | 2 | SEC ↗ |
| 4 | Glenview Capital ✦ | 8.46M | 0.0% | $186.38M | 4.7% | Held | 3 | SEC ↗ |
| 5 | Arrowstreet Capital ✦ | 6.99M | -53.1% | $154.07M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 6.98M | -14.0% | $153.76M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 7 | Millennium Management ✦ | 6.54M | -44.6% | $144.19M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 8 | Viking Global Investors ✦ | 6.50M | -14.1% | $143.34M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 9 | Marshall Wace ✦ | 5.16M | +87.8% | $113.63M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 10 | D. E. Shaw & Co. ✦ | 2.51M | -31.3% | $55.30M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 2.39M | -31.2% | $52.57M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 2.05M | +148.3% | $45.17M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 13 | Norges Bank ✦ (passief) | 1.75M | +15.4% | $38.55M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 1.20M | -66.9% | $26.45M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 686.46K | -4.0% | $15.13M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Greenlight Capital (DME Capital) ✦ | 468.55K | +44.2% | $10.33M | 0.5% | ▲ Add | 3 | SEC ↗ ×2 |
| 17 | Wellington Management ✦ | 185.91K | +2.1% | $4.10M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 18 | GAMCO Investors ✦ | 105.60K | -18.6% | $2.33M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | ARK Investment Management ✦ | 100.44K | -18.9% | $2.21M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 19.22K | +9.4% | $423,675 | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 21 | Bridgewater Associates ✦ | 9.39K | -59.5% | $207,022 | 0.0% | ▼ Trim | 3 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Point72 Asset Management | $9.33M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 646 houders, 666.61M aandelen, $16.70B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 2.52K aand · $98,841
Director · 367.60K aand · $14.36M
Officer · 4.50K aand · $174,221
Officer · 314 aand · $12,153
Officer · 2.50K aand · $94,077
Director · 415 aand · $15,459
Officer · 6.95K aand · $261,224
Officer · 18.60K aand · $680,291
Director · 17 aand · $593
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie